{"name":"Azienda Ospedaliera San Gerardo di Monza","slug":"azienda-ospedaliera-san-gerardo-di-monza","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Switch to TDF/FTC/RPV after 24 weeks","genericName":"Switch to TDF/FTC/RPV after 24 weeks","slug":"switch-to-tdf-ftc-rpv-after-24-weeks","indication":"HIV-1 infection in treatment-experienced or treatment-naive patients","status":"marketed"},{"name":"Immediate switch to TDF/FTC/RPV","genericName":"Immediate switch to TDF/FTC/RPV","slug":"immediate-switch-to-tdf-ftc-rpv","indication":"HIV-1 infection in treatment-naive or treatment-experienced adults","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Propofol + Remifentanyl","genericName":"Propofol + Remifentanyl","slug":"propofol-remifentanyl","indication":"Induction and maintenance of general anesthesia","status":"phase_3"},{"name":"Sevoflurane + Remifentanyl","genericName":"Sevoflurane + Remifentanyl","slug":"sevoflurane-remifentanyl","indication":"General anesthesia for surgical procedures","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Sevoflurane + Fentanyl","genericName":"Sevoflurane + Fentanyl","slug":"sevoflurane-fentanyl","indication":"General anesthesia for surgical procedures","status":"phase_3"}]}],"pipeline":[{"name":"Switch to TDF/FTC/RPV after 24 weeks","genericName":"Switch to TDF/FTC/RPV after 24 weeks","slug":"switch-to-tdf-ftc-rpv-after-24-weeks","phase":"marketed","mechanism":"A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents.","indications":["HIV-1 infection in treatment-experienced or treatment-naive patients"],"catalyst":""},{"name":"Immediate switch to TDF/FTC/RPV","genericName":"Immediate switch to TDF/FTC/RPV","slug":"immediate-switch-to-tdf-ftc-rpv","phase":"marketed","mechanism":"A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-naive or treatment-experienced adults"],"catalyst":""},{"name":"Propofol + Remifentanyl","genericName":"Propofol + Remifentanyl","slug":"propofol-remifentanyl","phase":"phase_3","mechanism":"Propofol and remifentanil together provide rapid-onset sedation and analgesia by depressing the central nervous system through GABA potentiation and opioid receptor agonism, respectively.","indications":["Induction and maintenance of general anesthesia","Sedation in mechanically ventilated patients in intensive care settings"],"catalyst":""},{"name":"Sevoflurane + Fentanyl","genericName":"Sevoflurane + Fentanyl","slug":"sevoflurane-fentanyl","phase":"phase_3","mechanism":"Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while fentanyl is an opioid analgesic that binds to mu-opioid receptors to provide analgesia and sedation.","indications":["General anesthesia for surgical procedures","Balanced anesthesia with analgesia during surgery"],"catalyst":""},{"name":"Sevoflurane + Remifentanyl","genericName":"Sevoflurane + Remifentanyl","slug":"sevoflurane-remifentanyl","phase":"phase_3","mechanism":"Sevoflurane is a general anesthetic that induces unconsciousness and amnesia, while Remifentanil is a potent opioid analgesic that provides pain relief.","indications":["General anesthesia for surgical procedures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNTllubEh1SVBHZm8wYWNrcGFVd2RZRi04cUd3Q0pYSGFId0U4emZaekozcEhISExCNXFWcXJqdWxEeUxnM3MyLVpnMW9xZTlzZmNSNFVQaVpjZkRJZDhuaUcxOG9Bcm1XTGhxNXgxN2xvTTBQVnZEbEhvbldONTNFSE1Gc2VuOFpISVBYQXlrNkRPUmc2THFGV3B1UnljZHFUN0tZUVh3ZnIwbnlZNDJSR1pqaF9hWDNQWmFGTHlqTGxTTGc0eFE?oc=5","date":"2017-09-19","type":"trial","source":"Clinical Trials Arena","summary":"Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL - Clinical Trials Arena","headline":"Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}